agºÍ¼Ç

À´Ô´£ºÓ¢ÎÄÂúµÄ£¬×÷Õߣº £¬£º

ÚÀ£¬ÎÒ¸úÄ㽲ࣣ¬×î½üÓиöÅóÓÑ´Ó±±·½¿Ëµ½¹ðÁÖÀ´ÂÃÓΣ¬ÎÊÎÒÄÏÍ·ÕòÕ¾½ÖÃ÷ϸÊǸöɶ×Ó¹¤¾ß¡£ÎÒ¹þ¹þһЦ£¬Õâ¸öÂÌýÆðÀ´Ïñ¸öµØÃû¹þ£¬ÆäʵÊÇÎÒÃǹðÁÖÈË˽²ØµÄ¡°ÀÏζµÀµØÍ¼¡±¡£ÄãÏþµÃ²»£¬ÕâµØ·½¿´ËÆÆÕͨ£¬ÀïÃæµÄ½²¾¿¿©£¬ÕæµÎÊǵֵÃÉÏÒ»¹øÈÈÌÚÌڵĹðÁÖÃ×·Û£¡

ÄÏÍ·ÕòÕ¾½ÖÃ÷ϸ£¬¾¿¾¹ÊÇɶ×ÓÍæÒâ¶ùࣣ¿

Ïà¹ØÍ¼Æ¬

Ê×ÏÈÂÄÏÍ·ÕòÕ¾½ÖÃ÷ϸ£¬ÆäʵÊÇÎÒÃǹðÁÖÕâ±ß¼¸ÌõÀϽÖÏï×ÓµÄͳ³Æ¡£ÀÏÒ»±²È˽²£¬ÕâÀïÊÇÄÏÍ·ÕòÒÔǰ×îÈÈÄֵĵط½£¬Õ¾½ÖÂ¾ÍÊÇÄÇЩСÉÌ··¡¢Ìôµ£×ӵġ¢°Ú̯µÄ£¬ÖÕÄêÀÛÔÂÕ¾ÔÚ½Ö¿Ú×öÉúÒâÁ¨¡£ÖÁÓÚ¡°Ã÷ϸ¡±ÄØ£¬¿ÉÒÔÕâôÀí½â£¬¾ÍÊǰÑÕâЩÀϽÖÉÌÆÌµÄÃÅ·¡¢ÌØÉ«Ò»¸ö¸öÞÛÇå³þ¡£

ÄãÈç¹ûµÚÒ»´Î¿ËÕâЩ½ÖÏï×Ó£¬¿ÉÄÜ»á¾õµÃÂÒÔãÔãµÄ¡ª¡ªÐ¡ÏïÈÆÀ´ÈÆÈ¥ÏñÍõ³ÇÀïÍ·µÄÃÔ¹¬£¬Ì¯Î»°ÚµÃÃÜÃÜÂéÂ飬ÖÖÖÖߺºÈÉù²»¾øÓÚ¶ú¡£¿ÉÊÇ£¬ÕæÕýÏþµÃÃŵÀµÄÀϹðÁÖ£¬×ß½øÈ¥à££¬ÄÇÊÇÏñ·­ÊéÒ»Ñù£¬·­µ½ÄÄÒ»Ò³¶¼ÓоªÏ²£¡

ÃŵÀÒ»£º³ÔµÄºÈµÄ£¬²ØÔÚ²»ÆðÑ۵ĽÇÂä

ÄÏÍ·ÕòÕ¾½ÖÃ÷ϸÀ×îÓÐȤµÄ¾ÍÊÇÄÇЩ²ØÔÚ½ÇÂäÀïµÄС³Ô̯×Ó¡£Äã¿´ÂÄÇ¿­ÎÒÄêÇá×Ó³£¿ËÒ»ÌõÏï×Ó³ÔÓͲ裬ÄǼҵêÃÅÁ³Ð¡µÃ¸úÖñͲһÑù£¬ÍâµØÈË¿´Á˾ø¶Ô²»»áÍ£½Å£¬µ«ÎÒ¸úÄ㽲ࣣ¬ÄÇζµÀÕæµÄÏã·­ÌìÁË£¡

ÓÐÒ»»Ø£¬ÎÒ´øÅóÓѿˣ¬¸Õ½øÏï×Ó¾ÍÎŵ½Ò»¹ÉËÖըСºÓÓãµÄÏãζ¡£ÅóÓÑÎÊÎÒ£º¡°Õâɶ×ӵط½ÕâôÏã°¡£¿¡±ÎÒЦ×Å˵£º¡°ÄãµÈ×Å£¬¿´ÎÒ½ÌÄã¸ö¡®ÀϹðÁÖÃØ¼®¡¯¡£¡±È»ºóÎÒ´øËûÕÒµ½ÁËÏï×ÓÉî´¦Ò»¸öÀÏ̫̫µÄС̯£¬Ëý¼ÒµÄÕ¨ºÓÓãÅäÉÏÌØÖÆµÄËáÀ±½´£¬³ÔÆðÀ´¸ÂàԴ࣬¼òÖ±ÊÇÉàÍ·¶¼ÒªÌøÎ裡

͵͵¸æËßÄ㣺ÄÏÍ·ÕòÕ¾½ÖÃ÷ϸÀïÍ·£¬±ð¿´ÄÇЩÀϾÉС̯²»ÆðÑÛ£¬µ«Ö»ÒªÓÐÑÌ»ðζºÍÈËÆø£¬°Ë³ÉÊDzØ×Å·ÏÎïµÄ¡£¼Ç×Å£¬ÎÅζµÀ¡¢¿´ÅŶÓ£¬ÕâÁ½ÕÐ׼û´í£¡

ÃŵÀ¶þ£ºÊÖ¹¤ÒÕÆ·£¬ÖµµÃÂýÂýÌÔ

³Ô±¥ºÈ×ãÁËࣣ¬ÄÏÍ·ÕòÕ¾½ÖÃ÷ϸÁíÓÐÒ»¸öºÃÍæµÄµØ·½£¬¾ÍÊÇÌÔÊÖ¹¤ÒÕÆ·¡£ÕâÀïµÄÀϽÖ̯×Ó£¬ÓÐЩÊÇ׿´«µÄÊÖÒÕÈË£¬×öµÄ¹¤¾ß¾«ÖÂÓÖËíµÀ¡£ºÃ±ÈÄǸöµñľͷµÄÕÅʦ¸µ£¬ËûµñµÄ¹ð»¨Ä¾¹Ò¼þ£¬ÎÅÆðÀ´¶¼Óйɵ­µ­µÄÏã棬¹ÒÔÚ³µÀïÍ·£¬ÄǽÐÒ»¸öÊæ·þ¡£

Ïà¹ØÍ¼Æ¬

²»¹ýÄãÒª¼ÇµÃŶ£¬ÕâЩµØ·½ÌÖ¼Û»¹¼ÛÊÇ»ù±¾¹¦¡£ÄãÒªÊÇÖ±½ÓÌÍÇ®Âò£¬¿ÉÄܻᱻЦ¡°ÐÂÏÊÈË¡±¡£×îºÃµÄ²½·¥ÊǶàÁÄÁÄ£¬ÎÊÎʹ¤ÒÕ¡¢ÊÖ·¨£¬Áĵ½Ê¦¸µ¿ªÐÄÁË£¬Ëû¿ÉÄÜ»¹»á¸øÄã´ò¸ö¡°ÓÑÇé¼Û¡±¡£

ÀϹðÁÖµÄ×ܽ᣺ÂýÂý×ߣ¬ÂýÂý¿´

ÕÕÎÒ¿´À´à££¬ÄÏÍ·ÕòÕ¾½ÖÃ÷ϸÕâ¸öµØ·½£¬×îÖØÒªµÄ¾ÍÊÇÒ»¸ö¡°Âý¡±×Ö¡£ÄãÒªÂýÂý×ߣ¬ÂýÂý¿´£¬ÂýÂýƷ棬²Å»ªÕæÕý¸ÐÊܵ½¹ðÁÖµÄÀÏζµÀºÍÈËÇéζ¡£±ðÏë×ÅÒ»ÏÂÎç¾ÍÄÜÅÜÍ꣬ÅܵÿìÁË£¬Ðí¶àºÃ¹¤¾ßÄã¶¼¿´²»µ½¡£


ÁôµãÏëÍ·£ºÄãÎÊ£¬ÎÒ´ð

Äã¿ÉÄÜ»áÎÊ£º¡°Ê¦¸µ£¬Äã¾õµÃÄÏÍ·ÕòÕ¾½ÖÃ÷ϸÀïµÄ¹¤¾ß×îÖµµÃÂòµÄÊÇɶ×Ó£¿¡±

ÎÒµÄÃÕµ×£º¡°Õâ¸öÂҪ¿´Äãϲ»¶É¶¿©¡£Ï²»¶³ÔµÄ¾ÍÕÒÄÇЩÀÏ̯×Ó£¬Ï²»¶°²ÅžÍÌÔµãľµñ£¬Ï²»¶ÊµÓõÄÂ¿ÉÒÔ¿´¿´ÊÖ¹¤²¼Ð¬¡ª¡ª´©ÆðÓÖÈíÓÖÇᣬ×ß·Ïñ²ÈÔÚÔÆÉÏ¡£¡±

Ïà¹ØÍ¼Æ¬

±êÇ©£ºÄÏÍ·ÕòÕ¾½ÖÃ÷ϸ¡¢¹ðÁÖÀϽ֡¢ÊÖ¹¤ÒÕÆ·¡¢ËíµÀС³Ô¡¢ÀϹðÁÖζµÀ

¡¶ÉòÑôÇìÐÒ½ÖÁíÓÐÂôµÄÂð¡·

Óë´Ëͬʱ£¬ÎļþÒ²¸øµØ·½Áô³ö²Ù×÷¿Õ¼ä£¬ºÃ±È£¬ÔÊÐíµØ·½¶Ô°üÀ¨ÊÊÀÏ»¯ÔÚÄÚµÄÖÇÄܼҾӲúÆ·×ÔÖ÷ÖÆ¶¨²¹Ìù±ê×¼£¬ÒÔ¼°µØ·½¿ÉÔÚÏû·ÑÆ·ÒԾɻ»ÐÂÕþ²ß¿ò¼ÜÄÚ×ÔÖ÷ºÏÀíÈ·¶¨²¹ÌùÆ·ÀàºÍ±ê×¼¡£

¡¶ÄÏͨк»ðºÃÈ¥´¦¡·

Serplulimab demonstrates unique advantages in treating various solid tumors via its differentiated mechanism.The drug not only induces stronger PD-1internalization¡ªreducing PD-1receptor presence on T cells for rapid and potent immune activation[1]¡ªbut also minimizes PD-1-mediated recruitment of the co-stimulatory molecule CD28,thereby preserving CD28signaling[2-4],enhancing downstream AKT activity[5],and promoting sustained T-cell activation.Focused on gastrointestinal cancers and lung cancer,serplulimab has been approved for the treatment of squamous non-small cell lung cancer(sqNSCLC),extensive-stage small cell lung cancer(ES-SCLC),ESCC,and non-squamous non-small cell lung cancer(nsqNSCLC).Up to date,it has been approved in over40countries and regions including China,the U.K.,Germany,Singapore,and India,covering nearly half of the global population and accelerating global accessibility.The results of4pivotal trials of serplulimab were published in the Journal of the American Medical Association(JAMA),Nature Medicine,Cancer Cell and British Journal of Cancer,respectively.It has also received orphan drug designations granted by the US FDA,the European Commission,Swissmedic,Korea MFDS and Mexico COFEPRIS.

¡¶¿ª·âСºúÍ¬ÌØÊâЧÀÍÓÐÄÄЩ¡·

Î§ÈÆÔöÇ¿ÃñÉú¸£ìí£¬¹ãÎ÷ÈË´ó³£Î¯»áÖÆ¶¨¾«ÉñÎÀÉúÌõÀý£¬ÐÞ¸ÄÄþ¾²Éú²úÌõÀý£¬ÐÞ¶©¶¯Îï·ÀÒßÌõÀý¡¢½û¶¾ÌõÀý¡£Ö¸µ¼ÓñÁÖÊгǫ̈¹ãÎ÷Êײ¿·¨ÖÎÏç´å½¨ÉèÔö½øÌõÀý£¬±±º£¡¢·À³Ç¸ÛÊгöÌ¨ÑøÈ®ÖÎÀíÌõÀý¡£

ÍøÕ¾µØÍ¼